SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (522)3/17/1999 1:53:00 AM
From: scaram(o)ucheRead Replies (1) | Respond to of 4974
 
Good stuff!

I have one comment about the Duke work..... it's very convincing work, but it demonstrates only very weak activity for angio in inhibiting the proliferation of endothelial cells. That is, they convincingly describe the receptor, but.... who cares?

But, Gawwwwwwd, what a neat story..... tumors feeding on dying cells, a unique mechanism for growth.

But, now, returning to the real world of pharmaceuticals......



To: Mike McFarland who wrote (522)3/17/1999 11:48:00 AM
From: aknahowRespond to of 4974
 
Not necessarily the news:

IBD 197 Industry Group Rankings of price performance put Medical-biomed/Genetics sector of 178 companies in 13 th place, up from 15 th last week 16 th three months ago.

No doubt that biotechs are a hot group and getting hotter. If and when those big pharmas that have said they are interested actually do buy, this sector could become one of the hottest, even replacing internet stocks from the top 4 spots.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News